About us

2006

2015

2016

2020

2021

current

"Founded in 2021, Van Overeem Nuclear B.V. has grown into a key player in radioactive material distribution."
Philippe van Overeem
Professional Biography

Philippe van Overeem

Philippe Van Overeem was raised in a close-knit family environment. His parents established IDB Holland in 1982, a company originally focused on the import and export of radiopharmaceuticals and calibration sources. During his academic tenure at the University of Applied Sciences in Tilburg, The Netherlands, Philippe gained early industry exposure through internships in the field of Nuclear Medicine. Notably, in 2004, he internedat DraxImage in Montreal, Canada. Under the mentorship of Dr. Richard Flanagan, he acquired hands-on experience with radionuclide production and dispensing, including Xe‑133, Cr‑51, I‑125, I‑131, and I‑125 brachytherapy seeds for prostate cancer treatment.
History of

Van Overeem bv

2006 - 2015
Upon graduation in 2006, Philippe joined the family company IDB Holland. At that time, the company was already manufacturing Lutetium‑177 chloride at the NRG facilities in Petten, initially under non-GMP conditions. Recognizing the need for compliance and scalability, IDB Holland began constructing its own GMP-certified facilities in Baarle-Nassau in 2008, achieving certification in 2010.
Philippe played a key role in expanding the Lu‑177 market, successfully introducing it in markets including Jordan, Saudi Arabia, Malaysia, Brunei, South Africa, and Canada. Parallel to these efforts, IDB Holland began global distribution of the iThemba Ge‑68/Ga‑68 generator, contributing to the company’s significant growth. In 2015, IDB Holland obtained EMA marketing authorization for Lu‑177 chloride as a radiopharmaceutical precursor.
2016 - 2020

In 2016, IDB Holland was acquired by big pharma, fostering a collaborative environment between the two entities.

Following another acquisition in 2018, Philippe continued to serve as Country Manager for the BeNeLux region until December 2020.

2021 - current

In January 2021, Philippe founded Van Overeem Nuclear B.V. (VON) in Breda, The Netherlands. The company secured a facility comprising offices, a GDP-compliant storage area, and two dedicated bunkers for radioactive materials. Following the successful acquisition of RAM, transportation, and GDP licenses, VON commenced operations in the import, export, and distribution of pharmaceuticals, radiopharmaceuticals, radiochemicals, and radioactive sources. Since its inception, VON has grown from a two-person team to fifteen employees as of 2025.

Also in 2021, Philippe co-founded TerThera with a business partner. The company aims to advance the use of Terbium‑161 in Nuclear Medicine, both in pre-clinical and select clinical applications. Production of Tb‑161 began in 2022, with bi-weekly manufacturing currently in place. A key milestone for 2025 was the launch of a GMP-compliant Tb‑161 product with an external partner.

By 2026, TerThera aims to operate a fully owned GMP production facility in Breda. The property has been secured, and installation of cleanrooms and hot cells is underway.